Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 8/2014

01-08-2014 | Review Article

Benefit-Risk Assessment of Orlistat in the Treatment of Obesity

Authors: Priya Sumithran, Joseph Proietto

Published in: Drug Safety | Issue 8/2014

Login to get access

Abstract

Orlistat, an inhibitor of intestinal lipase, has been available for the treatment of obesity for nearly two decades. In conjunction with a hypocaloric diet, orlistat treatment results in a placebo-subtracted reduction in body weight of around 3 kg at 1 year, and increases the likelihood of achieving clinically significant (≥5 %) weight loss by around 20 %. Orlistat-induced weight loss also confers modest improvements in systolic and diastolic blood pressure, low-density lipoprotein (LDL) cholesterol, glycemic parameters, and progression to diabetes in people with impaired glucose tolerance. Overall, it has a good safety profile, and serious adverse events (including reports of severe kidney and liver injury) are rare. However, a high rate of gastrointestinal side effects limits adherence to treatment.
Literature
1.
2.
National Health and Medical Research Council. Clinical Practice Guidelines for the Management of Overweight and Obesity in Adults. 2013.
3.
Williamson D, Pamuk E, Thun M, et al. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40–64 years. Am J Epidemiol. 1995;141:1128–41.PubMed
4.
5.
Johansson K, Neovius M, Hemmingsson E. Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014;99:14–23.PubMedPubMedCentral
6.
Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–32.PubMed
7.
Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992–5.PubMed
8.
Moran TH, Kinzig KP. Gastrointestinal satiety signals II. Cholecystokinin. Am J Physiol Gastrointest Liver Physiol. 2004;286:G183–8.PubMed
9.
Gutzwiller JP, Goke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 1999;44:81–6.PubMedPubMedCentral
10.
Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY[3-36] physiologically inhibits food intake. Nature. 2002;418:650–4.PubMed
11.
Rezek M. The role of insulin in the glucostatic control of food intake. Can J Physiol Pharmacol. 1976;54:650–65.PubMed
12.
Morley JE, Flood JF. Amylin decreases food intake in mice. Peptides. 1991;12:865–9.PubMed
13.
Batterham RL, le Roux CW, Cohen MA, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab. 2003;88:3989–92.PubMed
14.
Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature. 2000;404:661–71.PubMed
15.
Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597–604.PubMed
16.
Rosenbaum M, Hirsch J, Gallagher DA, et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr. 2008;88:906–12.PubMed
17.
18.
19.
Apfelbaum M, Vague P, Ziegler O, et al. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 1999;106:179–84.PubMed
20.
Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761–75.PubMed
21.
Hogan S, Fleury A, Hadvary P, et al. Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase. Int J Obes. 1987;11(Suppl 3):35–42.PubMed
22.
Hauptman J, Jeunet F, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr. 1992;55(Suppl):309S–13S.PubMed
23.
Zhi J, Melia A, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994;56:82–5.PubMed
24.
Zhi J, Melia A, Funk C, et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol. 1996;36:1006–11.PubMed
25.
26.
Sjöstrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167–73.PubMed
27.
28.
Franz M, VanWormer J, Crain L, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107:1755–67.PubMed
29.
Padwal R, Rucker D, Li S, et al. Long-term pharmacotherapy for obesity and overweight (review). Cochrane Database Syst Rev. 2003; CD004094.
30.
Hutton B, Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr. 2004;80:1461–8.PubMed
31.
Davidson M, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA. 1999;281:235–42.PubMed
32.
Rössner S, Sjöstrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res. 2000;8:49–61.PubMed
33.
Hauptman J, Lucas C, Boldrin M, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9:160–7.PubMed
34.
Karhunen L, Franssila-Kallunki A, Rissanen P, et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes. 2000;24:1567–72.
35.
Hill J, Hauptman J, Anderson J, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-year study. Am J Clin Nutr. 1999;69:1108–16.PubMed
36.
Richelsen B, Tonstad S, Rössner S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients. Diabetes Care. 2007;30:27–32.PubMed
37.
Johansson K, Sundström J, Neovius K, et al. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Obes Rev. 2010;11:777–91.PubMed
38.
Zhou Y-H, Ma X-Q, Wu C, et al. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2012;7:e39062.PubMedPubMedCentral
39.
Siebenhofer A, Jeitler K, Horvath K, et al. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev. 2013; CD007654.
40.
Norris S, Zhang X, Avenell A, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Arch Intern Med. 2004;164:1395–404.PubMed
41.
Mannucci E, Dicembrini I, Rotella F, et al. Orlistat and sibutramine beyond weight loss. Nutr Metab Cardiovasc Dis. 2008;18:342–8.PubMed
42.
Muls E, Kolanowski J, Scheen A, et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes. 2001;25:1713–21.
43.
Bergholm R, Tiikkainen M, Vehkavaara S, et al. Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes. Diabetes Care. 2003;26:1667–72.PubMed
44.
Mittendorfer B, Ostlund R, Patterson B, et al. Orlistat inhibits dietary cholesterol absorption. Obes Res. 2001;9:599–604.PubMed
45.
Suter P, Marmier G, Veya-Linder C, et al. Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size. Atherosclerosis. 2005;180:127–35.PubMed
46.
Gabriel F, Samson C, Abejuela Z, et al. Postprandial effect of orlistat on the peaking of lipid level after sequential high fat meals. Int J Endocrinol Metab. 2012;10:458–63.PubMedPubMedCentral
47.
Nakou E, Filippatos T, Georgoula M, et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin. 2008;24:1919–29.PubMed
48.
Dattilo A, Kris-Etherton P. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320–8.PubMed
49.
Jacob S, Rabbia M, Meier M, et al. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009;11:361–71.PubMed
50.
Berne C, et al. A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. Diabet Med. 2005;22:612–8.PubMed
51.
Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2002;4:415–23.PubMed
52.
Hollander P, Elbein S, Hirsch I, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care. 1998;21:1288–94.PubMed
53.
Kelley D, Bray G, Pi-Sunyer F, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. Diabetes Care. 2002;25:1033–41.PubMed
54.
Miles J, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;25:1123–8.PubMed
55.
Heymsfield S, Segal K, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000;160:1321–6.PubMed
56.
Torgerson J, Hauptman J, Boldrin M, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004;27:155–61.PubMed
57.
Gillies C, Abrams K, Lambert P, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;334:299–307.PubMedPubMedCentral
58.
National Institute for Health and Clinical Excellence. Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. NICE clinical guideline 43; 2006.
59.
Viner R, Hsia Y, Tomsic T, et al. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis. Obes Rev. 2010;11:593–602.PubMed
60.
Chanoine J-P, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents. JAMA. 2005;293:2873–83.PubMed
61.
Van Gaal L, Broom J, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol. 1998;54:125–32.PubMed
62.
Smith S, Stenlof K, Greenway F, et al. Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicentre trial. Obesity. 2011;19:1796–803.PubMed
63.
Fabricatore A, Wadden T, Moore R, et al. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev. 2009;10:333–41.PubMedPubMedCentral
64.
Padwal R, Kezouh A, Levine M, et al. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes. 2007;31:1567–70.
65.
Beerman B, Melander H, Säwe J, et al. Incorrect use and limited weight reduction of orlistat (Xenical) in clinical practice. Eur J Clin Pharmacol. 2001;57:309–11.
66.
Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes. 2001;25:1095–9.
67.
Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532–46.PubMed
68.
Holecki M, Zahorska-Markiewicz B, Nieszporek T, et al. The influence of a 3-month weight-reduction therapy with Orlistat on serum vitamin B12 and folic acid concentration in obese women. Int J Obes. 2006;30:1017–8.
69.
Colman E, Fossler M. Reduction in blood cyclosporine concentrations by orlistat. N Engl J Med. 2000;342:1141–2.PubMed
70.
Zhi J, Moore R, Kanitra L, et al. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharm. 2003;43:428–35.
71.
Bigham S, McGuigan C, MacDonald B, et al. Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat. Epilepsia. 2006;47:2207.PubMed
72.
Kent S. Loss of control of HIV viremia associated with the fat malabsorption drug orlistat. AIDS Res Hum Retroviruses. 2012;28:961–2.PubMed
73.
Bentley D, Young A-M, Rowell L, et al. Evidence of a drug-drug interaction linked to inhibition of ester hydrolysis by orlistat. J Cardiovasc Pharmacol. 2012;60:390–6.PubMed
74.
Madhava K, Hartley A. Hypothyroidism in thyroid carcinoma follow-up: orlistat may inhibit the absorption of thyroxine. Clin Oncol. 2005;17:492–3.
75.
Xiao D, Shi D, Yang D, et al. Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs. Biochem Pharmacol. 2013;85:439–47.PubMedPubMedCentral
76.
Zhi J, Melia A, Guerciolini R, et al. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol. 1996;36(7):659–66.PubMed
77.
MacWalter R, Fraser H, Armstrong K. Orlistat enhances warfarin effect. Ann Pharmacotherapy. 2003;37:510–2.
78.
Zhi J, Melia A, Koss-Twardy S, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol. 1995;35:521–5.PubMed
79.
Melia A, Mulligan T, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol. 1996;36:654–8.PubMed
80.
Melia A, Zhi J, Koss-Twardy S, et al. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol. 1995;35:840–3.PubMed
81.
Zhi J, Moore R, Kanitra L, et al. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol. 2002;42:1011–9.PubMed
82.
Weber C, Tam Y, Schmidtke-Schrezenmeier G, et al. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Eur J Clin Pharmacol. 1996;51:87–90.PubMed
83.
Hartmann D, Güzelhan C, Zuiderwijk P, et al. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol. 1996;50:421–4.PubMed
84.
Melia A, Zhi J, Zelasko R, et al. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. Eur J Clin Pharmacol. 1998;54:773–7.PubMed
85.
Hilger E, Quiner S, Ginzei I, et al. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. J Clin Psychopharmacol. 2002;22:68–70.PubMed
86.
Karamadoukis L, Shivashankar G, Ludeman L, et al. An unusual complication of treatment with orlistat. Clin Nephrol. 2009;4:430–2.
87.
Courtney A, O’Rourke D, Maxwell A. Rapidly progressive renal failure associated with successful pharmacotherapy for obesity. Nephrol Dial Transplant. 2007;22:621–3.PubMed
88.
Singh A, Sarkar S, Gaber L, et al. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis. 2006;49:153.
89.
Kwan T, Chadban S, Mckenzie P, et al. Acute oxalate nephropathy secondary to orlistat-induced enteric hyperoxaluria. Nephrology. 2013;18:241–2.PubMed
90.
Coutinho A, Glancey G. Orlistat, an under-recognised cause of progressive renal impairment. Nephrol Dial Transplant. 2013;28(Suppl 4):iv172–4.PubMed
91.
Ferraz R, Tiselius H, Heiberg I. Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion. Kidney Int. 2004;66:676–82.PubMed
92.
Sarica K, Akarsu E, Erturhan S, et al. Evaluation of urinary oxalate levels in patients receiving gastrointestinal lipase inhibitor. Obesity. 2008;16:1579–84.PubMed
93.
Weir M, Beyea M, Gomes T, et al. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med. 2011;171:703–4.PubMed
94.
MacLaughlin H, Macdougall I. Rapidly progressive renal failure associated with successful pharmacotherapy for obesity. Nephrol Dial Transplant. 2007;22:2403–5.PubMed
95.
96.
97.
Douglas I, Langham J, Bhaskaran K, et al. Orlistat and the risk of acute liver injury: self-controlled case series study in UK Clinical Practice Research Datalink. BMJ. 2013;346:f1936.PubMedPubMedCentral
98.
99.
Sergeant A, Milne G, Shaffrali F. Lichenoid eruption associated with orlistat. Br J Dermatol. 2006;154:1020–1.PubMed
100.
101.
Gonzalez-Gay M, Garcia-Porua C, Lueiro M, et al. Orlistat-induced cutaneous leukocytoclastic vasculitis. Arthritis Rheum. 2002;47:566–7.
102.
Sheikh-Taha M, Ghosn S, Zeitoun A. Oral aphthous ulcers associated with orlistat. Am J Health Syst Pharm. 2012;69:1462–4.PubMed
103.
Ahmad F, Mahmud S. Acute pancreatitis following orlistat therapy: report of two cases. J Pancreas. 2010;11:61–3.
104.
Napier S, Thomas M. 36 year old man presenting with pancreatitis and a history of recent commencement of orlistat case report. Nutr J. 2006;5:19.PubMedPubMedCentral
105.
Buyukhatipoglu H. A possibly overlooked side effect of orlistat: gastroesophageal reflux disease. J Natl Med Assoc. 2008;100:1207.PubMed
106.
Azar S, Zantout M. Diabetic ketoacidosis associated with orlistat treatment. Diabetes Care. 2001;24:602.PubMed
107.
Benazzi F. Depression induced by orlistat (Xenical). Can J Psychiatry. 2000;45:87.PubMed
108.
109.
Ringman J, Mozaffar T. Myopathy associated with chronic orlistat consumption: a case report. Neuromuscul Disord. 2008;18:410–2.PubMed
110.
111.
Degen L, Matzinger D, Drewe J, et al. Role of free fatty acids in regulating gastric emptying and gallbladder contraction. Digestion. 2006;74:131–9.PubMed
112.
Ellrichmann M, Ritter P, Otte J, et al. Orlistat reduces gallbladder emptying by inhibition of CCK release in response to a test meal. Regul Pept. 2007;139:136–40.PubMed
113.
Ellrichmann M, Kapelle M, Ritter P, et al. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations. J Clin Endocrinol Metab. 2008;93:3995–8.PubMed
114.
Borovicka J, Schwizer W, Guttmann G, et al. Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor. Gut. 2000;46:774–81.PubMedPubMedCentral
115.
Mathus-Vliegen E, Van Ierland-van Leeuwen M, Terpstra A. Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity. Aliment Pharmacol Ther. 2004;19:601–11.PubMed
116.
O’Donovan D, Feinle-Bisset C, Wishart J, et al. Lipase inhibition attenuates the acute inhibitory effects of oral fat on food intake in healthy subjects. Br J Nutr. 2003;90:849–52.PubMed
117.
Pilichiewicz A, O’Donovan D, Feinle C, et al. Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88:3829–34.PubMed
118.
Feinle-Bisset C, Patterson M, Ghatei M, et al. Fat digestion is required for suppression of ghrelin and stimulation of peptide YY and pancreatic polypeptide secretion by intraduodenal lipid. Am J Physiol Endocrinol Metab. 2005;289:E948–53.PubMed
119.
Tai K, Hammond A, Wishart J, et al. Carbohydrate and fat digestion is necessary for maximal suppression of total plasma ghrelin in healthy adults. Appetite. 2010;55:407–12.PubMed
120.
Goedecke J, Barsdorf M, Beglinger C, et al. Effects of lipase inhibitor (orlistat) on cholecystokinin and appetite in response to a high-fat meal. Int J Obes. 2003;27:1479–85.
121.
Froehlich F, Hartmann D, Guezelhan C, et al. Influence of orlistat on the regulation of gallbladder contraction in man. Dig Dis Sci. 1996;41:2404–8.PubMed
122.
Trouillot T, Pace D, McKinley C, et al. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. Am J Gastroenterol. 2001;96:1888–94.PubMed
123.
Kocelak P, Zahorska-Markiewicz B, Jonderko K, et al. Long-term effects of lipase inhibition by orlistat on gastric emptying and orocecal transit time of a solid meal. J Gastroenterol. 2008;43:609–17.PubMed
124.
Svendsen M, Rissanen A, Richelsen B, et al. Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial. Obesity. 2008;16:327–33.PubMed
125.
Svendsen M, Helgeland M, Tonstad S. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome. J Hum Nutr Diet. 2009;22:55–63.PubMed
126.
Yanovski S, Yanovski J. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311:74–86.PubMedPubMedCentral
Metadata
Title
Benefit-Risk Assessment of Orlistat in the Treatment of Obesity
Authors
Priya Sumithran
Joseph Proietto
Publication date
01-08-2014
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 8/2014
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-014-0210-7

Other articles of this Issue 8/2014

Drug Safety 8/2014 Go to the issue

Current Opinion

Advancing the Field of Pharmaceutical Risk Minimization Through Application of Implementation Science Best Practices

Erratum

Erratum to: Association of Statin Use with Sleep Disturbances: Data Mining of a Spontaneous Reporting Database and a Prescription Database

Review Article

A Comparison of Active Adverse Event Surveillance Systems Worldwide

Current Opinion

Bridging Islands of Information to Establish an Integrated Knowledge Base of Drugs and Health Outcomes of Interest

Original Research Article

Improved Statistical Signal Detection in Pharmacovigilance by Combining Multiple Strength-of-Evidence Aspects in vigiRank

Original Research Article

Indicators of Drug-Seeking Aberrant Behaviours: The Feasibility of Use in Observational Post-Marketing Cohort Studies for Risk Management